Schill W B, Feifel M, Fritz H, Hammerstein J
Int J Androl. 1981 Feb;4(1):25-38. doi: 10.1111/j.1365-2605.1981.tb00687.x.
In vitro studies were performed to investigate the accessibility of acrosin to various proteinase inhibitors inside the intact acrosome of testicular, ejaculated, and uterine human spermatozoa. As test system the gelatin plate assay was used. For this assay it was shown formerly that a correlation exists between the size of the digested lysis areas (halo formation) and acrosin activity estimated with synthetic substrates. In addition, saturation of the gelatin substrate membranes with acrosin inhibitors including highly specific ones before application of spermatozoa completely prevented halo formation indicating that the gelatinolytic activity of human spermatozoa is caused exclusively by acrosin. When human spermatozoa were incubated with various acrosin inhibitors (concentration: 1 mmol/l) prior to application to the gelatin membrane, reduction of halo formation could not be observed, however. This result indicates that most of the tested acrosin inhibitors (9 naturally occurring protein inhibitors, 2 microbial peptide inhibitors, 19 synthetic inhibitors) were unable to penetrate the acrosomal membranes of testicular, ejaculated, and uterine human spermatozoa. Only 2 inhibitors caused moderate up to complete inhibition of the gelatinolytic activity of the spermatozoa if applied in concentrations between 1 and 10 mmol/l: the proteinase inhibitor aprotinin and the synthetic inhibitor NPGB (4-nitrophenyl 4-guanidinobenzoate). Obviously, human acrosomal membranes seem to be especially impenetrable to proteins, polypeptides, and synthetic agents. Those acrosin inhibitors penetrating the human sperm head membranes are either too toxic or the local concentration necessary for effective acrosin inhibition in vivo cannot be achieved within the male or female genital tract secretions. Therefore, acrosin inhibitors cannot be used for human contraception at present. Thus it is mandatory to continue the search for suitable acrosin inhibitors with low toxicity easily penetrating into the intact sperm acrosome.
进行了体外研究,以调查顶体蛋白酶在人睾丸精子、射出精子和子宫内精子完整顶体内对各种蛋白酶抑制剂的可及性。使用明胶平板试验作为测试系统。对于该试验,以前已经表明,消化裂解区域(晕圈形成)的大小与用合成底物估计的顶体蛋白酶活性之间存在相关性。此外,在应用精子之前,用包括高度特异性抑制剂在内的顶体蛋白酶抑制剂使明胶底物膜饱和,可完全阻止晕圈形成,这表明人精子的明胶分解活性完全由顶体蛋白酶引起。然而,当在将人精子应用于明胶膜之前用各种顶体蛋白酶抑制剂(浓度:1 mmol/L)孵育时,未观察到晕圈形成减少。该结果表明,大多数测试的顶体蛋白酶抑制剂(9种天然存在的蛋白质抑制剂、2种微生物肽抑制剂、19种合成抑制剂)无法穿透人睾丸精子、射出精子和子宫内精子的顶体膜。只有2种抑制剂在1至10 mmol/L的浓度下应用时,可导致精子明胶分解活性中度至完全抑制:蛋白酶抑制剂抑肽酶和合成抑制剂NPGB(4-硝基苯基4-胍基苯甲酸酯)。显然,人顶体膜似乎对蛋白质、多肽和合成剂特别难以穿透。那些能穿透人精子头部膜的顶体蛋白酶抑制剂要么毒性太大,要么在男性或女性生殖道分泌物中无法达到体内有效抑制顶体蛋白酶所需的局部浓度。因此,顶体蛋白酶抑制剂目前不能用于人类避孕。因此,必须继续寻找毒性低、易于穿透完整精子顶体的合适顶体蛋白酶抑制剂。